Everolimus, also known as RAD-001, is a drug marketed by Novartis under the tradenames Certican (for transplantation) and Afinitor (for oncology). It is a derivative of Rapamycin (sirolimus), and it works in a similar manner as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of certain cancers, as evidenced by the March 2009 FDA approval of everolimus for the treatment of advanced kidney cancer.Wikipedia
Everolimus is primarily metabolized by CYP3A4 and CYP3A5, and SNPs in these genes may therefore influence its metabolism. However, to date there do not appear to be any studies showing significant consequences of SNPs in these genes on everolimus dosage or clinical outcome.